🇺🇸United States·March 05, 2026·daily

S&P 500 Energy Sector SEC Filings — March 05, 2026

The sole filing in the USA S&P 500 Energy intelligence stream is an 8-K from Copper Property CTL Pass Through Trust, announcing a monthly cash distribution of $0.082844 per trust certificate, payable on March 10, 2026, to holders of record on March 9, 2026. This reflects positive sentiment (rated positive) and steady capital allocation focused on shareholder returns via distributions, with materiality at 6/10. No period-over-period comparisons, YoY/QoQ trends, insider trading activity, forward-looking guidance, M&A details, financial ratios, or operational metrics were disclosed in the filing, limiting quantitative trend analysis across the sector. The availability of the monthly report for the period ending February 28, 2026, on the investor website (www.ctltrust.net) enhances transparency. Key implication: This signals reliable income generation in the energy sector trust space, potentially appealing to yield-seeking investors amid stable cash flows, though absence of comparative data prevents identifying growth or margin trends at a portfolio level.

1 medium1 total filings

🇺🇸United States·March 05, 2026·daily

S&P 500 Financials Sector SEC Filings — March 05, 2026

Across the 416 pre-analyzed SEC filings from S&P 500 Financials and adjacent sectors (though data skews to energy, biotech, retail, and industrials), overarching themes include mixed FY2025 results with revenue growth in 62% of reporting companies (avg +12% YoY) offset by margin compression in 58% (avg -85 bps YoY), driven by higher operating costs and impairments; capital allocation favors buybacks/dividends in 28 companies (e.g., $7.5B Kroger repurchase completed, $2B authorized). Insider activity shows neutral conviction with appointments dominant (e.g., 15 new directors/CFOs) but few buys/sells. Forward-looking guidance is cautious with 45% raising revenue targets (avg +10%) but 32% trimming EBITDA/margins amid economic pressures. M&A accelerates (12 deals, avg $500M+ valuation, e.g., USA Rare Earth $73M acquisition), signaling consolidation. Portfolio-level trends: EBITDA flat/declining in 55% despite revenue beats, highlighting cost inflation; energy/biotech outliers with 20-50% YoY declines in key metrics. Implications: Favor resilient dividend payers and M&A targets; avoid margin squeezes in retail/energy.

227 high priority189 medium416 total filings

🇺🇸United States·March 05, 2026·daily

S&P 500 Technology Sector SEC Filings — March 05, 2026

Across 20 SEC filings from diverse sectors mislabeled under S&P 500 Technology stream, dominant themes include robust revenue growth in 9/20 companies (avg +35% YoY where quantified, e.g., Evommune +86%, Entravision +23%, CrowdStrike +22%) offset by widening net losses in 10/20 (e.g., CrowdStrike loss to $162.5M, Entravision to $79.2M) due to surging OpEx (avg +25% YoY). Mixed sentiment prevails (12/20 filings), with positive catalysts like biotech trials (Altimmune Q3 2026 RECLAIM data, Evommune 2Q/2H26 Phase 2b), capital allocation via dividends (Iridium $0.15/share, Entravision $0.20), M&A/divestitures (CYH $112M hospital sale Q2 2026 close, Genco vessel acquisition), and restructurings (Cumulus prepackaged Ch.11). Margin compressions hit 7/15 with data (avg -100bps, e.g., NCS services to 45%, Weave onboarding -153%), while cash positions strengthened in biotechs (Altimmune +107% YoY to $274M, Evommune to $216.7M). Insider activity limited to appointments (Acadia new director, Altimmune CEO change), no major buys/sells. Portfolio implications: Bullish on turnaround growth (Adial loss -40% YoY), bearish on bankruptcy risks (Cumulus); monitor Q2 2026 catalysts for alpha in undervalued assets.

14 high priority6 medium20 total filings

🇺🇸United States·March 05, 2026·daily

Nasdaq 100 Stocks SEC Filings — March 05, 2026

Across 22 NASDAQ-100 filings, mixed sentiment prevails with 12/15 annual reports showing average revenue growth of 25% YoY (range +9% Costco to +86% Evommune) driven by tech/services/advertising segments, but offset by profitability pressures including widened losses (e.g., +3% Evommune, +12% Metagenomi), impairments (Entravision $55M), and margin declines (NCS services 45% vs 49%). Biotech cluster (Altimmune, Evommune, Metagenomi, Adial) highlights pipeline catalysts and cash runways to 2027-28 despite revenue volatility (-52% Metagenomi). Media/comms face headwinds (Cumulus bankruptcy prep, Entravision media -20-32% YoY), while retail (Costco +9% sales) and shipping (Genco acquisition) shine. Capital allocation steady with dividends (Iridium $0.15, Entravision $0.20 unchanged), reverse split (Aditxt 1:8), and M&A (CYH $112M sale Q2 2026). Portfolio implications: Favor consumer/biotech catalysts, avoid distressed media, monitor restructuring votes/debt closes for near-term volatility.

15 high priority7 medium22 total filings

🇺🇸United States·March 05, 2026·daily

Dow Jones 30 Stocks SEC Filings — March 05, 2026

Across 118 SEC filings from the USA Dow Jones 30 intelligence stream (covering diverse sectors but focused on blue-chips and related), overarching themes include resilient YoY revenue growth averaging +15% in 35/118 companies (e.g., Grid Dynamics +17.5%, CrowdStrike +22%, Hippo +26%) offset by widespread margin compression (-100 to -200 bps in 28 firms like OLAPLEX -27.6% Adj EBITDA drop) and mixed sentiment (62% mixed, 18% positive). Period-over-period trends show QoQ improvements in Q4 for 22 companies (e.g., Ranger Energy revenue +10% QoQ) but FY losses widening in tech/services (CrowdStrike net loss -$162.5M vs -$15.2M prior). Capital allocation remains shareholder-friendly with buybacks/dividends in 15 filings (e.g., BJ's $117.7M Q4 repurchases, Ranger 994k shares), while forward guidance signals caution (e.g., OLAPLEX FY26 sales flat, Grove revenue decline). M&A/divestitures active (Six Flags $331M parks sale, Aptiv spin-off), and insider conviction mixed with no major sales but leadership changes (Trulieve CAO termination). Portfolio implications: Favor margin-resilient growers like Invivyd (revenue doubled) over compressors; monitor energy transition plays (Greenidge AI/HPC shift). Critical developments: AI-driven growth (Grid Dynamics AI 25% of Q4) vs expense surges, positioning selective longs in tech/finance amid macro softness.

70 high priority48 medium118 total filings

🇺🇸United States·March 05, 2026·daily

S&P 500 Consumer Discretionary Sector SEC Filings — March 05, 2026

Across 71 SEC filings from diverse sectors mislabeled under S&P 500 Consumer Discretionary (including energy, financials, tech, and true disc like entertainment), overarching themes include robust revenue/production growth averaging 20-50% YoY in 25+ companies (e.g., Granite Ridge +27% prod, FTC Solar +149% Q4 rev, Profound Medical +50%), tempered by persistent net losses or margin compression in 30+ firms due to higher opex/LOE (e.g., flyExclusive retail -39% Q4, Mobile Infra rev -5%). Capital allocation shines with aggressive buybacks (Zillow +$1.25B to $1.3B capacity, Paycom +$200M) and dividend hikes (Korn Ferry +14.6% to $0.55), signaling management conviction amid mixed sentiment (45/71 mixed/neutral). Forward-looking data reveals optimistic 2026 guidances in energy/tech (SandRidge 6.4-7.7 MMBoe, Bridger $135-145M rev, TriSalus $60-62M), spin-offs (Aptiv Versigent April 1), and divestitures (Six Flags $331M parks sale). Portfolio-level trends show outperformance in production/reserves growth (energy avg +15-28% YoY) vs deteriorating retail/consumer metrics (flyExclusive fractional retail -8% YTD, NIKE $300M restructuring charges). Critical implications: prioritize capital return plays and guided growth; avoid prolonged loss-makers like Research Frontiers (cash -67%).

32 high priority39 medium71 total filings

🇺🇸United States·March 05, 2026·daily

S&P 500 Healthcare Sector SEC Filings — March 05, 2026

Across 31 SEC filings from the USA S&P 500 Healthcare stream (with broader S&P exposure), overarching themes include robust revenue growth in healthcare/biotech (e.g., TriSalus 53% YoY to $45.2M, Caribou 12% to $11.2M) and select financials (South Plains 13.6% NII growth), offset by pervasive margin compression (TriSalus GM -150bps to 84.6%, Ciena -20bps to 43.8%) and widening net losses (TriSalus -30.6% to $39.2M, Caribou flat at $148M amid impairments). Mixed sentiment dominates (14/20 detailed), driven by top-line beats/guidance reaffirms (TriSalus exceeded FY25, reaffirms 2026 $60-62M) but elevated costs/op-ex (S&M/G&A up double-digits across biotech) and litigation costs (Moderna $950M settlement). Capital allocation favors buybacks (Ciena $80.5M, News Corp $1B program) and dividends (NewLake Q1 2026 $0.43/share), with healthcare firms pursuing M&A/raises (TriSalus $46M offering, Moderna royalty-free license). Portfolio-level trends show 7/12 revenue reporters >20% YoY growth but 6/8 with op loss expansion; proxy season ramps with 8 Apr 2026 meetings signaling comp votes amid strong TSR (BNY 178%, First Business 235%). Critical developments: litigation resolutions (Moderna) and board enhancements (PacBio AI expert) provide catalysts, implying selective healthcare upside amid financial stability.

17 high priority14 medium31 total filings

🇺🇸United States·March 04, 2026·daily

S&P 500 Consumer Staples Sector SEC Filings — March 04, 2026

Across 50 filings from the USA S&P 500 Consumer Staples intelligence stream (broadly including food, beverages, household, and adjacent sectors), overarching themes include heightened governance activity with 12+ proxy statements (DEF 14A/DEFA14A) signaling board refreshes, annual meetings, and shareholder proposals, alongside mixed financial results showing revenue growth in 6/20 reporting companies (avg +30% YoY outliers like Kontoor +21%, Bankwell +25% total revenue) but declines in 7/20 (avg -8% YoY, e.g., Cracker Barrel -7.9%). Margin trends are bifurcated: expansions in 5 companies (ImmuCell +1140bps to 41.4%, Pulmonx Q4 +400bps to 78%) versus compressions in 4 (Kontoor op margin -240bps to 10.7%). Capital allocation leans defensive with steady dividends (Horizon $0.06/month, Helmerich $0.25/quarter) and buybacks (Kontoor repurchased at $67.58 avg), while divestitures (Hain Celestial Snacks sale) and M&A progress (Horizon-Monroe merger) aim to deleverage. Forward-looking catalysts cluster in Q2 2026 (10+ AGMs April-May) and biotech milestones (Cellectar EMA Q3 2026), but cash burns (Cellectar -43% YoY) and net losses (12/25 firms) flag funding risks. Portfolio-level, neutral-mixed sentiment (60% mixed/neutral) implies sector resilience amid consumer pressures, favoring dividend payers and turnaround plays.

25 high priority25 medium50 total filings

🇺🇸United States·March 04, 2026·daily

S&P 500 Industrials Sector SEC Filings — March 04, 2026

Across 69 SEC filings from S&P 500 Industrials and related sectors, dominant themes include mixed financial results with revenue growth in 12/20 key earners (avg +15% YoY, e.g., Black Rock Coffee +24.5%, CPS Technologies +54%) offset by widespread margin compression (avg -150 bps in 8/15 reporters) and net loss expansions (e.g., Ocugen +25%, Rigetti +8%). Biotech and tech firms highlight clinical catalysts (e.g., Ocugen OCU410ST interim Q3 2026, EyePoint DURAVYU topline mid-2026) amid cash burn concerns, while industrials like Babcock & Wilcox show backlog surges (+470% YoY). SPAC activity intensifies with extensions (Goldenstone to Dec 2026) and mergers (Bleichroeder-Pasqal $2B valuation), signaling M&A momentum. Capital allocation leans toward buybacks/dividends (Abercrombie $450M repurchase, Bath & Body $400M) but dilutions via equity raises dilute shareholders (Regen BioPharma +77M shares). Portfolio-level trends flag deteriorating profitability despite top-line resilience, with forward guidance cautious (e.g., Cracker Barrel revenue -2.5-4.5% FY2026). Actionable implications: Favor backlog-rich industrials, monitor biotech catalysts, avoid high-dilution names.

34 high priority35 medium69 total filings

🇺🇸United States·March 04, 2026·daily

S&P 500 Energy Sector SEC Filings — March 04, 2026

Across the four filings in the S&P 500 Energy stream, Hess Midstream LP dominates with positive capital allocation via a $60M accretive repurchase program, signaling strong management conviction and commitment to 5% annual distribution growth through 2028 while preserving $1B in flexibility. Real Brokerage Inc. highlights a pristine balance sheet with zero long-term debt, leases, or liabilities, and 210.5M shares outstanding, underscoring financial stability amid no ICFR changes. BRT Apartments Corp. reports a smooth CFO transition with vesting of 42,800 restricted shares but forfeiture of RSUs, maintaining neutral sentiment. A Paradise Acquisition Corp.'s SPAC pursuit of Enhanced Ltd. reveals mixed sentiment due to high risks like regulatory scrutiny and minimal revenue, contrasting sector peers. No uniform period-over-period trends emerge as filings lack comprehensive financial comparisons, but capital returns and low-debt profiles point to defensive positioning. Key implication: Energy midstream shows shareholder-friendly actions amid limited sector catalysts on March 4, 2026.

3 high priority1 medium4 total filings

🇺🇸United States·March 04, 2026·daily

S&P 500 Financials Sector SEC Filings — March 04, 2026

Across 365 SEC filings from diverse S&P 500 Financials-adjacent sectors (including banks, insurers, healthcare, energy, retail), overarching themes include robust YoY revenue growth averaging +15% in high-materiality filings (e.g., National Vision +9% FY, Viemed +21% FY, BillionToOne +100% FY), but widespread margin compression (-100 to -200 bps YoY in 12/20 key reports like Gran Tierra -37% netback, Grocery Outlet impairments) and mixed profitability with 40% reporting net losses or widened deficits. Capital allocation trends favor shareholder returns (buybacks in 15 filings totaling $500M+, dividends steady/growing in 10 like Horizon $0.18/share Q2), while M&A/refinancings (e.g., Cooper-Standard debt swap, SSR Mining $1.5B asset sale) signal deleveraging. Insider activity sparse but positive conviction in repurchases; forward guidance optimistic for 2026 (revenue +10-40% in 20 filings). Portfolio-level: Healthcare/biotech shows pipeline catalysts (Ocugen Phase 3 topline Q1 2027) offsetting cash burn; energy mixed on production vs. prices; retail impairments flag caution. Actionable: Favor growth names with raised guidance amid macro volatility.

193 high priority172 medium365 total filings

🇺🇸United States·March 04, 2026·daily

S&P 500 Technology Sector SEC Filings — March 04, 2026

Across the 8 filings in the USA S&P 500 Technology intelligence stream, proxy season kicks off prominently with Texas Instruments (TXN) DEF 14A and DEFA14A filings highlighting the April 16, 2026 annual meeting, alongside neutral Nuveen fund proxies, signaling routine governance but no major shifts. Broadcom Inc. dominates with blockbuster Q1 FY2026 results: revenue +29% YoY to $19.3B, AI revenue exploding +106% YoY to $8.4B, and Q2 guidance of $22B (+47% YoY), underscoring semiconductor/AI strength amid sector volatility. ImmuCell shows modest recovery with 2025 sales +4.3% YoY to $27.6M and gross margins expanding +1,140bps to 41.4%, though offset by one-time charges leading to net loss; Nuveen Quality Municipal's VRDP redemption extension to 2056 is a liquidity win. Other filings like NCS Multistage and AParadise SPAC reveal sparse data and high risks, respectively. Portfolio-level trends show YoY revenue acceleration in semis (Broadcom outlier at +29%) vs modest growth elsewhere, with capital returns via Broadcom's new $10B buyback and dividend. Mixed sentiment prevails (3/8 mixed), but AI-driven semis signal outperformance potential amid proxy governance focus.

3 high priority5 medium8 total filings

🇺🇸United States·March 04, 2026·daily

Nasdaq 100 Stocks SEC Filings — March 04, 2026

Across 14 NASDAQ-100 related SEC filings from March 4, 2026, dominant themes include robust semiconductor growth led by Broadcom's 29% YoY revenue surge and 106% AI acceleration, contrasted by mixed biotech results with PepGen narrowing losses but facing FDA holds and ImmuCell achieving 41.4% gross margins (up from 30%) despite net losses from write-downs. Proxy season kicks off with TXN and Nuveen funds scheduling April 16 meetings, signaling governance focus amid stable capital structures like NAD's VRDP redemption extension to 2056. Shipping (Costamare) shows long-term charter stability with TEU-weighted durations up to 6.9 years, while SPACs (AParadise) highlight high-risk combinations. Portfolio-level trends reveal 3/5 companies with revenue growth averaging 27% YoY (Broadcom, ImmuCell, AITX implied), margin expansions in ops-heavy firms (+1,140bps for ImmuCell), but persistent net losses in biotechs (PepGen -4% YoY op ex decline). Capital returns shine via Broadcom's $10B buyback and dividend, positioning AI/semicon as outperformers vs. biotech underperformers on cash burn. Implications favor rotating into semis/AI catalysts while monitoring biotech clinical risks and proxy outcomes for governance shifts.

6 high priority8 medium14 total filings

🇺🇸United States·March 04, 2026·daily

Dow Jones 30 Stocks SEC Filings — March 04, 2026

Across 121 SEC filings from diverse US companies (despite DJ30 focus, spanning retail, healthcare, energy, tech, and industrials), overarching themes include mixed financial results with 22/45 quantifiable revenue reporters showing YoY growth averaging +15% (e.g., Republic Airways +20.6%, Veeva +16%), but 12 experiencing declines averaging -8% (e.g., Cracker Barrel -7.9%, Bath & Body Works -2%), driven by margin compression in retail (-150bps avg in 5 cos) and consumer weakness offset by M&A-fueled gains. Capital allocation leans bullish with 9 share repurchase programs (e.g., Innovative $100M, National Vision $50M renewed), debt reductions (e.g., Republic $231.6M repaid), and dividends maintained/raised (e.g., Global Water $0.30396 annualized), signaling management conviction amid 15 guidance issuances mostly maintained/raised for 2026. Insider activity is sparse but positive where noted (e.g., no major sales); M&A/divestitures active in 12 filings (e.g., Ziff Davis sale to Accenture, Diversified Energy $245M acquisition). Critical developments: 2 bankruptcies/delistings (Charles & Colvard Ch11, Vicarious NYSE delisting), but portfolio-level trends show improving cash flows (15/25 with data up YoY) and backlog growth (e.g., Orion +470% implied via Babcock). Implications: Rotate to growth sectors like healthcare/tech (avg +12% revenue) from retail; monitor Q1 2026 catalysts for alpha.

65 high priority56 medium121 total filings

🇺🇸United States·March 04, 2026·daily

S&P 500 Consumer Discretionary Sector SEC Filings — March 04, 2026

Across 69 filings from S&P 500 Consumer Discretionary and adjacent sectors, overarching themes include mixed revenue growth with top-line expansion in 7/15 retail/fitness firms (avg +10% YoY, e.g., Black Rock Coffee +24.5%, Abercrombie +6%) offset by widespread margin compression (avg -150bps across 9 reporters) and operational losses; capital returns remain robust with buybacks/dividends in 8 firms (e.g., Abercrombie $450M repurchase, Brown-Forman $400M). M&A/divestitures active (Ziff Davis sale to Accenture, Farmer Bros acquisition at $1.29/share), alongside leadership transitions signaling AI/strategic pivots (FactSet AI officers). Period-over-period trends show YoY revenue growth in 12/25 quantified filers (+avg 8%) but net income declines in 10/20 (-avg 25%), with forward guidance cautious (e.g., Abercrombie 3-5% sales growth FY26). Portfolio-level patterns flag consumer resilience in apparel/restaurants but vulnerability in fitness/specialty retail amid cost pressures; actionable now: prioritize buyback-heavy names pre-AGMs.

38 high priority31 medium69 total filings

🇺🇸United States·March 04, 2026·daily

S&P 500 Healthcare Sector SEC Filings — March 04, 2026

Across 30 filings in the USA S&P 500 Healthcare stream (with broader financial/REIT inclusions), dominant themes include clinical progress in biotech/oncology (Citius 86% ORR Phase 1, Cellectar Q3 2026 EMA submission) offsetting cash burns (-43% at Cellectar to $13.2M), mixed revenue trends (Niagen +30% YoY to $129.4M, Sight Sciences -3% to $77.4M), and strong financial recoveries (Bankwell net income +260% YoY to $35.2M, First Financial +67.5% to $79.2M). Period-over-period highlights: NII surges avg +50% YoY in banks (Alerus +61.1%), provisions down sharply (Bankwell -95%), but deposits -3-4% across lenders and op ex rises (Niagen Q4 +59%). Capital allocation shows dividend hikes (First Financial to $2.04/share) vs constrained buybacks (Procaccianti prorated 3.6%). Forward-looking catalysts cluster mid-2026 (Cellectar Phase 1b data, Sight Sciences 6-14% revenue growth to $82-88M). No insider buys/sells detailed, but director resignations (MVB over governance) flag concerns. Implications: Bullish oncology combos and bank turnarounds; bearish dilution/funding risks in biotechs; monitor 2026 guidance execution for alpha.

12 high priority18 medium30 total filings

🇺🇸United States·March 03, 2026·daily

S&P 500 Consumer Staples Sector SEC Filings — March 03, 2026

Across 34 filings in the USA S&P 500 Consumer Staples intelligence stream (broadly encompassing food, beverages, household, and personal care with some adjacent), key themes include robust revenue growth in reporting companies averaging +29% YoY for Q4 2025 (Rigel +41%, Kontoor +46%, Fuel Tech +37%, Accel +7.5%), margin expansions in high performers (Accel EBITDA +18.9% YoY Q4, Fuel Tech gross +44.6%), and active M&A with premiums (Select Medical 18-25%, Diamond Hill merger approved). Leadership transitions were prevalent and largely positive (Wyndham CFO appt with outlook reaffirm, Massimo CFO, Energy Fuels smooth CEO succession), alongside capital allocation via buybacks (CCEP repurchased 749k shares), debt repayments (Haemonetics $300M full payoff), and equity facilities (PMGC $7.5M prepaid purchase). Forward-looking catalysts cluster in Q2 2026 (mergers, spin-offs), with positive guidance where provided (Rigel $275-290M 2026 rev, Kontoor +9% rev/+15% EPS). Portfolio-level patterns show 6/10 earnings reporters beating YoY revenue trends despite isolated declines (Accel Illinois -2.5% locations), signaling resilient consumer demand but mixed regional/segment performance; sentiment leans positive (14/34 positive/mixed bullish). Risks include softening pricing (SmartStop web rates -13.3% YoY Jan 2026) and M&A execution hurdles, presenting alpha via arb plays and growth outliers.

15 high priority19 medium34 total filings

🇺🇸United States·March 03, 2026·daily

S&P 500 Industrials Sector SEC Filings — March 03, 2026

Across 56 SEC filings from the USA S&P 500 Industrials stream (broadly including adjacent sectors like pharma/biotech due to filing mix), overarching themes include robust revenue growth in 18/56 companies averaging +22% YoY (e.g., Limbach +24.7%, Rigel +60% FY product sales), offset by margin compression in 9/56 (avg -150 bps, e.g., Limbach gross margin -160 bps) and mixed EBITDA trends (up in 12, down in 8). Capital allocation leans shareholder-friendly with buybacks (Limbach $50M program) and debt refinancings lowering costs (Adtalem -50 bps margins, Howmet $1.2B notes for acquisition). Forward-looking catalysts cluster in H1-H2 2026: 7 guidances raised/issued (e.g., Limbach $730-760M rev), 5 trial readouts (Amylyx Q3, Karyopharm mid-2026), Honeywell Aerospace spin-off progress, and M&A closes (Howmet CAM by 2026). Industrials-specific patterns show M&A/outperformance (Howmet $1.8B deal, Limbach ODR +40.6%), while pharma dominates positive pipeline (MIRA Phase 1 success, Rigel R289 H2 data). Portfolio implications: overweight growth industrials/services amid resilient demand, monitor pharma trial risks; no broad insider selling detected, but repurchases signal conviction in 3 firms.

21 high priority35 medium56 total filings

🇺🇸United States·March 03, 2026·daily

S&P 500 Energy Sector SEC Filings — March 03, 2026

Across the two filings in the USA S&P 500 Energy intelligence stream, key themes emerge around strategic growth via M&A and strong executive performance incentives, though filings span adjacent high-growth areas like security tech and biotech with energy-adjacent applications. Knightscope's acquisition of Event Risk LLC highlights accretive expansion into managed security services with double-digit growth assets, while Stoke Therapeutics rewards CEO Ian F. Smith with a $697,125 bonus for 150% goal achievement in 2025. No period-over-period financial trends (YoY/QoQ revenue, margins) or insider trading activity were detailed, limiting quantitative portfolio comparisons, but both exhibit positive sentiment (Knightscope 9/10 materiality, Stoke 6/10). Forward-looking catalysts include Knightscope's GSX conference presentation later in 2026 and plans for additional acquisitions, signaling portfolio-level M&A momentum. Capital allocation appears shareholder-friendly via growth investments, with no dividend/buyback data disclosed. Overall, bullish signals dominate, but lack of detailed metrics prevents robust sector margin/growth trend synthesis.

2 high priority2 total filings

🇺🇸United States·March 03, 2026·daily

S&P 500 Financials Sector SEC Filings — March 03, 2026

Across 248 SEC filings from S&P 500 Financials and adjacent sectors (despite diverse inclusions like healthcare, mining, and tech), dominant themes include robust M&A activity (e.g., 12+ deals like Select Medical's $3.9B takeover at 25% premium, RAPT's $58/share tender), mixed Q4/FY2025 earnings with revenue growth averaging +10% YoY in reporting firms (e.g., Accel +8.1%, Evolus +12%) but frequent margin compression (-100 to -200 bps in 15+ cos like STAAR, THOR), and aggressive capital returns via buybacks/dividends (e.g., Pinterest $2B repurchase, MarketWise $0.45 special dividend). Leadership transitions signal stability (20+ CEO/CFO changes, mostly positive like Wyndham's CFO appt), while debt refinancings/issuances (25+ events, e.g., RGA $400M notes, Leidos $1.4B) bolster liquidity amid high interest environments. Forward guidance shows cautious optimism (e.g., Limbach $730-760M rev +13% mid, EVgo $410-470M +20%), but risks from delistings (Trinseo), restatements (Century Aluminum), and covenant waivers persist. Portfolio-level trends: 40% filings positive sentiment, 35% mixed, with YoY revenue up in 60% of earners but EBITDA mixed; insider patterns limited but sales rare, buys absent; catalysts cluster mid-2026 (closings, earnings). Implications: overweight M&A targets/premiums, monitor margin squeezes in cyclicals, favor cap alloc leaders for returns.

96 high priority152 medium248 total filings